7.35
-0.02 (-0.27%)
| Previous Close | 7.37 |
| Open | 7.41 |
| Volume | 100,395 |
| Avg. Volume (3M) | 1,297,935 |
| Market Cap | 701,985,024 |
| Price / Sales | 606.20 |
| Price / Book | 7.12 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2026 |
| Operating Margin (TTM) | -1,621.58% |
| Diluted EPS (TTM) | -1.39 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 4.72% |
| Current Ratio (MRQ) | 9.08 |
| Operating Cash Flow (TTM) | -56.39 M |
| Levered Free Cash Flow (TTM) | -30.34 M |
| Return on Assets (TTM) | -41.77% |
| Return on Equity (TTM) | -71.90% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Shattuck Labs, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.67 |
|
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 14.36% |
| % Held by Institutions | 64.06% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |